Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational,
12-week study to compare the efficacy, dose response, and safety of tadalafil once a day
versus placebo in men with signs and symptoms of benign prostatic hyperplasia, including
lower urinary tract symptoms.